Biotechnology
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
Read
Commented by Nico Popp on May 29th, 2025 | 07:00 CEST
The next AI revolution is being spearheaded by these hidden champions: Palantir, NetraMark, Roche
Are you still working the same way you did five years ago? Let's be honest: AI has changed a lot. The opportunities are enormous, especially in biotechnology. Already in 2024, one in four venture capital dollars for AI projects went to the healthcare sector, according to Silicon Valley Bank. Although around 80% of the industry already works with AI, there is a wide range of applications, with significant differences between experiments and groundbreaking innovations. We present three AI beneficiaries from the healthcare sector and explain how investors can profit.
Read
Commented by Nico Popp on May 28th, 2025 | 06:55 CEST
Smart innovations for strong returns: BioNTech, BioNxt Solutions, and Siemens Healthineers
For a new drug to hit the market, it has to outperform existing alternatives – so innovation is key for biotech companies. In medical technology, too, innovations must first and foremost benefit patients. However, research and development are expensive. We analyze how BioNTech, BioNxt Solutions, and Siemens Healthineers are driving innovation and what that means for investors.
Read
Commented by André Will-Laudien on May 27th, 2025 | 07:15 CEST
Up to 1500% with high tech and artificial intelligence – Incredible price movements at Evotec, NetraMark Holdings, and D-Wave
Artificial intelligence can now be found in all sectors of the economy. Search processes, validations, and historical comparisons now take place in a matter of seconds, and a dramatic leap in productivity is on the horizon. The capital markets have set themselves the task of evaluating these future processes. This is no easy task, as most topics cannot be viewed in isolation. Last week, renewed tariff threats led to a short-term price correction. These losses had to be offset yesterday, with political denials from the US sending share prices skyrocketing again. Under intense pressure, investors now have to decide whether investments promise short- or medium-term success. We use three examples to show how challenging this has become. Where are the opportunities and risks?
Read
Commented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST
Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva
In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?
Read
Commented by Armin Schulz on May 22nd, 2025 | 07:10 CEST
Overlooked gems? Why artificial intelligence will catapult Novo Nordisk, NetraMark, and UnitedHealth to the forefront
The pharmaceutical industry is undergoing a historic transformation. Artificial intelligence is compressing drug development times from decades to months, reducing costs by billions, and unlocking therapies for previously untreatable diseases. Algorithms sift through genome data, simulate drug candidates, and optimize clinical trials with a precision that surpasses that of human researchers. This disruption is not only creating medical milestones but also lucrative opportunities for investors. Today, we look at three candidates and analyze the current situation at Novo Nordisk, NetraMark Holdings, and UnitedHealth.
Read
Commented by Fabian Lorenz on May 21st, 2025 | 07:00 CEST
Stocks on the verge of MULTIPLYING? BioNTech, D-Wave, and hot stock Argo Living Soils aim to revolutionize their markets! Buy now?
These companies want to turn billion-dollar markets upside down: Argo Living Soils, BioNTech, and D-Wave. Argo Living Soils aims to revolutionize infrastructure construction through nanotechnology. Concrete and asphalt are to become more durable and environmentally friendly through nanotechnology. This could, for example, make buildings and bridges better protected against earthquakes. The potential is enormous, and the hot stock is valued at less than CAD 10 million, offering the chance for a multiple increase. D-Wave has impressively demonstrated how quickly a revaluation can take place. Quantum computing has the potential to change the world. But big players like Alphabet, NVIDIA, and others also want a big piece of the pie. At BioNTech, the focus remains on the fight against cancer. The stock appears to have halted its sell-off, but analysts are lowering their price targets. Where is the right entry point now?
Read
Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
Read
Commented by Stefan Feulner on May 20th, 2025 | 07:05 CEST
Super Micro, NetraMark, Rigetti – Trump push promises potential
The suspension of tariffs between the two superpowers, the US and China, continues to boost technology and semiconductor stocks such as Nvidia and Super Micro Computer. Tech giant Apple, which initially suffered from the 145% tariffs imposed by US President Donald Trump, is also benefiting enormously from the current deal. AI stocks have also performed well in their wake and are poised for further upward momentum.
Read
Commented by Mario Hose on May 16th, 2025 | 14:00 CEST
Save the date and register now for free: From the raw materials boom to the AI revolution: Leading companies from five continents will present future opportunities on May 21, 2025, at the 15th International Investment Forum (IIF)
If you want to understand the trends of tomorrow, you need to hear directly from the people shaping them today. The 15th International Investment Forum (IIF) gives you that opportunity: On May 21, 2025, CEOs, investors, and thought leaders from across the globe will gather online to share insights from key sectors like industry, defense, mining, cleantech, biotech, AI, and more. In live presentations and interactive discussions, companies such as Germany's CENIT AG, Canada's First Phosphate Corp., dynaCert, Desert Gold, and Australia's Manuka Resources will provide exclusive insights into their strategies. The digital conference will be moderated by Stockhouse media star Lyndsay Malchuk, who is well-known for her incisive interviews. Why should you attend this event?
Read